Esketamine is under clinical development by Clexio Biosciences and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Esketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Esketamine (CLE-100) is under development for the treatment of major depressive disorder. The drug candidate is an adjunctive treatment and is administered by oral route. It acts by targeting glutamate ionotropic NMDA receptor. It was also under development for the treatment of bipolar depression.
Clexio Biosciences overview
Clexio Biosciences (Clexio) is a clinical-stage pharmaceutical company focused on the development of novel drugs, small molecules, and drug-device combinations for the treatment pain, depression and other central nervous system (CNS) indications. Its pipeline product portfolio include CLE-100, an oral NMDA receptor modulator for adjunctive therapy in major depressive disorder; CLE-300, disruptive platform of wearable drugs; CLE-400, a topical formulation for the treatment of PDN and CLE-500, a patient-controlled drug-device combination for immediate relief of cluster headaches. The company also developed a proprietary oral gastro-retentive drug delivery platform (CLE-600) used for both extending the absorption window and controlled release of multiple pill burdens of numerous drugs. Clexio is headquartered in Jerusalem, Israel.
For a complete picture of Esketamine’s drug-specific PTSR and LoA scores, buy the report here.